UNITED STATES INTERNATIONAL TRADE COMMISSION Washington, D.C.

In the Matter of

CERTAIN RADIO FREQUENCY MICRO-NEEDLE DERMATOLOGICAL TREATMENT DEVICES AND COMPONENTS THEREOF **Investigation No. 337-TA-1112**

NOTICE OF COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL DETERMINATION TERMINATING THE INVESTIGATION WITH RESPECT TO EIGHT PATENT CLAIMS

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination ("ID") (Order No. 13) issued by the presiding administrative law judge ("ALJ") that terminates the investigation with respect to eight patent claims.

FOR FURTHER INFORMATION CONTACT: Robert Needham, Office of the General Counsel, U.S. International Trade Commission, 500 E Street, SW., Washington, D.C. 20436, telephone (202) 708-5468. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street, SW., Washington, D.C. 20436, telephone (202) 205-2000. General information concerning the Commission may also be obtained by accessing its Internet server (https://www.usitc.gov). The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on May 15, 2018, based on a complaint filed by Syneron Medical Ltd. of Yokneam Illit, Israel; Candela Corporation of Wayland, Massachusetts; and General Hospital Corporation d/b/a Massachusetts General Hospital of Boston, Massachusetts (together, "Complainants"). 83 FR 22515-16. The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. § 1337, in the importation into the United States, the sale for importation, and the sale within the United

States after importation of certain radio frequency micro-needle dermatological treatment devices and components thereof that infringe one or more of claims 1, 2, 4, 9-11, 15, 20, and 21 of U.S. Patent No. 9,510,899 ("the '899 patent") and claims 1, 2, 4, 9-12, 17, and 18 of U.S. Patent No. 9,095,357 ("the '357 patent"). *Id.* at 22515. The Commission's notice of investigation named as respondents Invasix, Inc. of Lake Forest, California; Invasix, Ltd. of Yokneam, Israel; Inmode Md, Ltd. of Lake Forest, California; Ilooda Co., Ltd. of Suwon, Republic of Korea; Cutera, Inc. of Brisbane, California; Emvera Technologies, LLC of Cedartown, Georgia; Rohrer Aesthetics, LLC of Homewood, Alabama; Lutronic Corp. of Goyang, Republic of Korea; Lutronic, Inc. of Billerica, Massachusetts; Endymed Medical Inc. of New York, New York; Endymed Medical Ltd. of Caesarea, Israel; Sun Hwan E&B Co., Ltd. d/b/a/ SHEnB Co., Ltd. of Seoul, Republic of Korea; Aesthetics Biomedical, Inc. of Phoenix, Arizona; Cartessa Aesthetics of Hockessin, Delaware; Jeisys Medical, Inc. of Seoul, Republic of Korea; Perigee Medical LLC of Tracy, California; Lumenis Ltd. of Yokneam, Israel; and Pollogen Ltd. of Tel Aviv-Jaffa, Israel. Id. at 22516. The Office of Unfair Import Investigations is not participating in this investigation. Id.

On January 31, 2019, Complainants filed an unopposed motion to terminate the investigation in part by withdrawing its allegations with respect to claims 2, 9, 20, and 21 of the '899 patent and claims 2, 9, 17, and 18 of the '357 patent.

On February 5, 2019, the ALJ issued the subject ID, granting the motion and terminating the investigation with respect to those eight claims. No petitions for review of the ID were filed.

The Commission has determined not to review the subject ID.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Lisa R. Barton

Secretary to the Commission

Issued: February 19, 2019